Analysts at StockNews.com assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Get Free Report) in a research report issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Tenax Therapeutics Price Performance
NASDAQ TENX opened at $3.62 on Wednesday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $61.20. The business’s fifty day moving average price is $3.71 and its 200-day moving average price is $3.64.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.99) by $0.16. Research analysts anticipate that Tenax Therapeutics will post -6.68 EPS for the current fiscal year.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Recommended Stories
- Five stocks we like better than Tenax Therapeutics
- What is Forex and How Does it Work?
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Pros And Cons Of Monthly Dividend Stocks
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.